Our Products
About Us
Contact Us
Hello Sign In
Your Account
My Cart

Renalis Supplement Facts

Pin it
Learn more about the ingredients in Renalis.
 Renalis Supplement Facts

 Serving Size:  3 Capsules
 Servings Per Container:  30

Per Serving
Daily Value

  Vitamin B6 (as Pyridoxine HCL) 7.5 mg 375%

  Magnesium (as Magnesium Citrate) 250 mg 62%

  Chanca Piedra Extract (Phyllanthus niruri) (entire plant) 350 mg *

  Hydrangea Extract (Hydrangea arborescens) (root) 75 mg *

  Aloe Vera Extract (Aloe barbadensis) (leaf) 15 mg *

   Other Ingredients:  Vegetarian Capsule (Hypromellose), Rice Powder, Magnesium Stearate.
   *Daily Value Not Established

Daily Dosage: As a dietary supplement, take two capsules in the morning and one capsule in the evening with 8 ounces of water. Our suggested minimum serving is 3 capsules daily/maximum serving of 6 capsules daily. 45-60 days of continuous use is necessary for optimum results.


Renalis Research:

Hydrangea (Hydrangea arborescens) - Hydrangea has mild diuretic activity and has traditionally been used to treat kidney stones and prevent their formation (1). In certain cases managed only by a physician, a botanical formula including hydrangea has been used to assist with passage of calcium oxalate or phosphate stones that are no larger than 5mm in diameter, and in patients who are in good health (2).


Chanca Piedra (Phyllanthus niruri) - An herb with a long historical tradition in South America for patients with kidney stones, Phyllanthus has a body of scientific evidence supporting its use. In sixty-nine patients who tend to form calcium kidney stones, administration of Phyllanthus capsules for three months reduced urinary calcium levels when compared to placebo (3). Another study showed an inhibitory effect of Phyllanthus extract on calcium oxalate crystal growth and aggregation in human urine, suggesting that it may interfere with the early stages of stone formation (4). Research has also shown that the extract is not toxic to kidney cells (5).


Aloe vera - Aloe is better known for its laxative and wound healing effects. However, aloe also is useful in patients who tend to form kidney stones. One of it constituents, emodin, has mild diuretic activity. As well, aloe binds calcium and can rapidly decrease the growth rate of calcium crystals in the urine (6).


Magnesium citrate - This form of magnesium has added benefit with both components exerting effects in patients prone to kidney stone formation (7,8). Magnesium increases the solubility of calcium in the urine and decreases its absorption leading to decreased formation of calcium oxalate (making up 90% of kidney stones). Citrate increases urinary magnesium citrate levels and decreases urinary oxalate. In patients with a history of kidney stones, magnesium should be taken regularly to exert an alkali loading effect, thereby reducing the chance of calculus formation (9). Patients with idiopathic calcium urolithiais (ICU) tend to have more acidic urine and lower levels of free citrate, making magnesium citrate the ideal supplement (10). It appears magnesium citrate is most effective when taken with meals.


Vitamin B-6 - In a study of over 85000 women, the results showed that lower levels of vitamin B6 are associated with increased risk of developing kidney stones (11). The authors suggest that large doses of this vitamin may reduce the incidence of kidney stone formation. Suboptimal levels of vitamin B6 lead to increased urinary levels of oxalate and resultant stone formation in some patients (12). Children with a history of kidney stones have benefited from supplementation with vitamin B6, thereby reducing levels of urinary oxalate resulting in no stone formation in a 1 year follow-up, as well as resolution of abdominal pain and blood in the urine (13). Supplementation in adults also reduces the risk of recurrent calcium-oxalate stone formation (14).

Renalis References

  1. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.

  2. Yarnell E. Naturopathic Urology and Men's Health. Wenatchee, WZ: Healing Mountain Publishing;2001:212-213.

  3. Nishiura JL et al. Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res 2004 Oct;32(5):362-6. Epub 2004 Jun 19.

  4. Barros ME, Schor N, Boim MA. Effects of an aqueous extract from Phyllantus niruri on calcium oxalate crystallization in vitro. Urol Res 2003 Feb;30(6):374-9. Epub 2003 Jan 21.

  5. Campos AH, Schor N. Phyllanthus niruri inhibits calcium oxalate endocytosis by renal tubular cells: its role in urolithiasis.
     Nephron 1999;81(4):393-7.

  6. Anton R, Haag-Berrurier M. Therapeutic use of natural anthraquinone for other than laxative actions.  Pharmacology. 1980;20 Suppl 1:104-12

  7. Lindberg J, Harvey J, Pak CY.  Effect of magnesium citrate and magnesium oxide on the crystallization of calcium salts in urine: changes produced by food-magnesium interaction. J Urol. 1990 Feb;143(2):248-51.

  8. Wu N et al. Effects of magnesium citrate and phytin on reducing urinary calcium excretion in rats. World J Urol 1994;12(6):323-8.

  9. Jaipakdee S et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. J Med Assoc Thai 2004 Mar;87(3):255-63.

  10. Schwille PO et al. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 1999 Apr;27(2):117-26.

  11. Curhan GC et al. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 1999 Apr;10(4):840-5.

  12. Mitwalli A, Ayiomamitis A, Grass L, et al. Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. Int Urol Nephrol 1988;20:353-9.

  13. Rogowska-Kalisz A et al. [The results of conservative treatment of oxalate urolithiasis in children] Pol Merkuriusz Lek 2003 Jul;15(85):51-4.

  14. Rattan V et al. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers. Urol Res 1994;22(3):161-5.